A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia
Kenneth S. Bauer, Judith E. Karp, Tushar S. Garimella, Suhlan Wu, Ming Tan, Douglas D. Ross
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia'. Together they form a unique fingerprint.